Effect and Safety of dose-escalating treatment of Imidafenacin for Overactive Bladder : CLSS-modified-Self-Assessment Goal Achievement questionnaire
Not Applicable
- Conditions
- Overactive Bladder
- Registration Number
- JPRN-UMIN000004894
- Lead Sponsor
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
Not provided
Exclusion Criteria
1)Polyuria (daily urine volume >=3000mL) 2)Residual urine >=100mL 3)Suspect of prostate cancer 4)Indwelling catheter or self intermittent urinary catherization 5)The shift work and patients with irregular lifestyle 6)Bladder training conducted over the past 10 days 7)Active urinary tract infection 8)Having been given hormones or 5 alpha-reductase inhibitor within the past six months 9)Contraindication to imidafenacin (Primary angle-closure glaucoma , urinary retention , Obstructive intestinal disease, paralytic ileus, gastrointerstinal atony , myastania gravis ) 10)Judged as being unsuitable for the trial by the researcher.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1)CLSS-modified-Self-Assessment Goal Achievement questionnaire : CLSS-modified-SAGA 2)Overactive Bladder Symptom Score : OABSS
- Secondary Outcome Measures
Name Time Method 1) IPSS-QOL 2) residual urine volume 3) adverse events and side-effects